acamprosate
Adjunctive therapy • Brands: Campral
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Campral
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Glutamatergic/GABAergic modulator used to help maintain abstinence in alcohol use disorder after detoxification; best suited for people who are already alcohol-free and want support staying abstinent (label/guideline).
Metabolism & Half‑life
- Metabolism: Not significantly metabolized (label)
- Half‑life: Single-dose range 20–33 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Acamprosate calcium delayed-release tablets prescribing information — DailyMed (2025)
- Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis — JAMA (2014)
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder — American Journal of Psychiatry (2018)
- Anticraving therapy for alcohol use disorder: A clinical review — Neuropsychopharmacology Reports (2018)